UBS analyst Peter Grom increased his price target for Kimberly-Clark (KMB) to $110, citing steady core performance despite lingering Kenvue-related uncertainties, after the consumer goods giant reported better-than-expected quarterly profit driven by cost discipline and resilient demand.
TD Cowen raises Prudential Financial's price target to $113, maintaining a 'Hold' rating, as the insurer grapples with a misconduct scandal at its Japan life insurance unit affecting nearly 500 customers.
Stifel Nicolaus lowered its price target on Altria Group (MO) by $4 to $68, citing higher-than-expected operating costs. Despite near-term headwinds, the firm reaffirmed its Buy rating, pointing to the tobacco giant's resilient dividend profile and long-term earnings guidance.
Scotiabank has lowered its price target for Comcast (CMCSA), reflecting ongoing pressure in its core broadband business as the media giant reports higher-than-expected customer losses in Q4 and faces fierce competition from fiber and fixed-wireless rivals.
Roth Capital has upgraded Energy Fuels (UUUU) from 'Sell' to 'Neutral', raising its price target to $15. The move follows the uranium miner's strategic acquisition of Australian Strategic Materials, expanding its rare earths portfolio and positioning within Western critical mineral supply chains.
A fresh price target for Euronext Brussels-listed IT services firm Econocom Group has analysts and investors reassessing the company's trajectory. The update reflects evolving views on the company's strategic positioning and market conditions.
Takeda Pharmaceutical's (TSE:4502) recent share price rally has ignited a debate among investors. With the stock closing at ¥5,242, analysts are divided on its true worth, presenting a complex picture of fair value signals and future growth prospects.
A revised price target for Haivision Systems (TSX:HAI) is shifting the investment narrative, prompting a closer look at the video streaming technology firm's prospects amid evolving market conditions.
Bank of America has revised its price target for consumer goods giant Kimberly-Clark downward, citing sector-wide valuation pressures, even as the company reports resilient earnings and advances its transformation into a broader health and wellness player.
B. Riley Securities lowered its price target on Skyworks Solutions, citing ongoing softness in the Android smartphone segment that is expected to weigh on near-term guidance, despite strength from Apple's iPhone cycle and diversification efforts.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
Truist Securities raised its price target on Fifth Third Bancorp (FITB) following a robust quarterly performance driven by loan growth and fee income, while slightly adjusting its long-term earnings outlook due to acquisition timing and tax considerations.
Wells Fargo updates its long-term valuation for American Electric Power (AEP), raising its price target to $140, as the utility secures a major fuel cell investment and a 20-year power purchase agreement for a new Wyoming facility.
Truist Securities adjusted its price target for American Healthcare REIT (NYSE: AHR) downward slightly, while affirming a Buy rating. The move comes as the firm reassesses its outlook for the broader REIT sector heading into 2026.
Analyst firm Argus has raised its price target for Sanmina Corporation (SANM) to $200, maintaining a Buy rating following the company's better-than-expected Q1 2026 results and robust positioning in key growth markets.
USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.
Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
